Evolva Raises $27.5 Million
Evolva SA, a Swiss biotech company that uses a genetic chemistry platform to developer small molecule drugs, has raised CHF28 million ($27.5m) in Series B funding. Wellington Partners and return backer Aravis co-led the round, and were joined by new investors Auriga Partners and Vinci Capital – Renaissance PME. The investment is a precursor to Evolva's planned reverse merger with Arpida Ltd., which is listed on the Swiss stock exchange (SIX: ARPN). Evolva has raised around $20 million in VC funding from firms like Novartis Venture, Aravis, Sunstone Capital and Dansk Innovationsinvestering.
27 October 2009•3 mins read
